+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
FEMALE
ID06218303

Study of a Prototype MUC1 Vaccine With Hormone Therapy to Prevent Disease Progression in Women With Ductal Carcinoma In Situ

Led by Finn, Olivera, PhD · Updated on 2026-10-16

50

Participants Needed

1

Research Sites

96 weeks

Total Duration

AI-Summary

What This Trial Is About

This clinical trial is focused on women diagnosed with biopsy-confirmed ductal carcinoma in situ DCIS, a condition often detected through mammography that can sometimes progress to invasive breast cancer. The study aims to evaluate a prototype vaccine targeting MUC1, a tumor-associated antigen, to activate the immune system and potentially prevent disease progression in pre- and post-menopausal women with estrogen receptor-positive DCIS. The trial is a randomized Phase 1 study designed to understand immune activation and suppression mechanisms in this patient group and to guide future larger trials. Participants are assigned to one of two groups one group receives neoadjuvant hormone therapy with an aromatase inhibitor or selective estrogen receptor modulator SERM daily for about 12 weeks prior to surgery. The other group receives the same hormone therapy along with the MUC1 peptide vaccine combined with Hiltonol adjuvant administered subcutaneously at baseline, week 2, and week 10, followed by surgery around week 12. Patients in the vaccine group may also receive an optional booster vaccine six months after surgery. During the study, participants will undergo surgery after about 12 weeks of treatment. Researchers will assess immune response to the MUC1 vaccine at week 12 and monitor adverse events and the timing of planned surgery for up to two years. Other evaluations include blood tests, pathology assessments, and safety monitoring. The total participation duration may extend up to two years to evaluate both immunogenicity and safety outcomes.

CONDITIONS

Brief Title

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Research Team

K

Kelsey Mitch, RN, BSN

L

Lucia Borrasso, BS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here